Amide

Amide Technologies is a biotech startup offering on-demand complex peptide manufacturing at unprecedented speed, bridging the gap between traditional solid-phase peptide synthesis and biological expression. Founded on technology developed at MIT, Amide uses its proprietary Automated Fast-Flow Peptide Synthesis (AFPS) platform to synthesize peptides that other vendors cannot, including those with unnatural amino acids and artificial protein backbones. The company accepts orders other vendors refuse and ships urgent orders in less than a week, enabling rapid design-build-test cycles for biopharma customers. Amide raised $16.5M to expand its platform and expedite frontier drug discovery programs.